BDBM525575 US11174250, Example 2::US11174250, Example Table4.1.2::US11174250, Example Table4.3.2

SMILES CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cc(CN2CCOCC2)ccc1F

InChI Key InChIKey=HJPMPWYSTRBBLP-UHFFFAOYSA-N

Data  3 IC50  3 Kd

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 525575   

TargetWD repeat-containing protein 5(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525575(US11174250, Example Table4.1.2 | US11174250, Examp...)
Affinity DataKd:  11nMAssay Description:Exemplary compounds of the application were dissolved in 100% DMSO at 10 mM, assayed fresh, and then stored at −20° C. for repeat studies and o...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525575(US11174250, Example Table4.1.2 | US11174250, Examp...)
Affinity DataIC50: 939nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetWD repeat-containing protein 5(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525575(US11174250, Example Table4.1.2 | US11174250, Examp...)
Affinity DataKd:  11nMAssay Description:Exemplary compounds of the application were dissolved in 100% DMSO at 10 mM, assayed fresh, and then stored at −20° C. for repeat studies and o...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525575(US11174250, Example Table4.1.2 | US11174250, Examp...)
Affinity DataIC50: 939nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetWD repeat-containing protein 5(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525575(US11174250, Example Table4.1.2 | US11174250, Examp...)
Affinity DataKd:  11nMAssay Description:Exemplary compounds of the application were dissolved in 100% DMSO at 10 mM, assayed fresh, and then stored at −20° C. for repeat studies and o...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525575(US11174250, Example Table4.1.2 | US11174250, Examp...)
Affinity DataIC50: 939nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In DepthDetails
US Patent